Inquis Medical Corp.

Inquis Medical Corp. (Inquis Medical, Inc.) is a privately held medical device company headquartered in Menlo Park, California, founded in 2020 (some third-party databases list 2019). Its Rule 7.1 disclosure in the Delaware litigation states no parents or affiliates, and it remains venture-backed rather than public. Funding announced to date totals roughly $115 million, including a $40 million Series B (November 2024, led by Marshall Wace) and a $75 million Series C (January 2026, undisclosed strategic investor). Crunchbase/parsers-type listings put headcount in the 11–50 range; it has described itself as transitioning to commercial stage in 2025. Co-CEOs and co-founders are Vahid Saadat and Mojgan Saadat.

The company develops catheter-based mechanical thrombectomy systems for venous thromboembolic disease (pulmonary embolism and deep vein thrombosis). Its flagship product is the AVENTUS Thrombectomy System, which combines directional aspiration with proprietary tissue-sensing technology that reports real-time information about tissue at the catheter tip. A companion AVENTUS Clot Management System enables autologous blood reinfusion (filtered return of aspirated blood) during clot removal. AVENTUS received FDA 510(k) clearance for peripheral vascular indications in November 2023 (K232730), the clot management system in May 2024 (K240426), and an expanded pulmonary embolism indication in June 2025. It is a real operating company, not a patent assertion entity.

Litigation posture: Inquis appears in the tracked data only as a defendant (0 plaintiff cases, 1 defendant case) — consistent with an operating company being sued rather than an NPE. The single tracked matter is Inari Medical, Inc. v. Inquis Medical Corp., filed September 11, 2024 in the U.S. District Court for the District of Delaware (No. 1:24-cv-01023, Judge Colm F. Connolly). Venue reflects Inquis's Delaware incorporation rather than a plaintiff-friendly Texas district.

Inari — a competing VTE thrombectomy developer acquired by Stryker in February 2025 — asserted four patents (U.S. 11,890,180; 11,969,332; 11,974,909; 11,986,382) against the AVENTUS products, plus trade secret misappropriation and tortious interference claims, and Inquis filed counterclaims. The case has generated notable Delaware rulings on willfulness pleading and enhanced damages. Inquis has stated no parent or affiliate ownership.